DEFENSIN THERAPEUTICS ApS: Financial statements 2023
CVR: 35513280
Source: annual report 2023, Danish Business Authority
01/01/2023 – 31/12/2023
DEFENSIN THERAPEUTICS ApS (CVR 35513280) has filed annual accounts for 2023. In 2023, the company reported a net result of DKK -425,344 compared with DKK -473,890 the year before. Equity in the 2023 report amounted to DKK 1,380,154. The solvency ratio was 97.9%.
- Profit/Loss
- DKK -425,344
- Equity
- DKK 1,380,154
- Total Assets
- DKK 1,409,655
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2023 | - | - | -425K | 1.4M | - |
| 2022 | - | - | -474K | 1.7M | - |
| 2021 | 0 | - | -366K | 2.1M | - |
| 2020 | - | - | -2.3M | 2.5M | 0 |
| 2019 | - | - | -1.7M | 4.8M | 1 |
Official annual report
Fetch this data via API
Every Danish company, financial statement and ownership record, straight into your own systems or your AI assistant via MCP.
See the API documentationEvents in 2023
DEFENSIN THERAPEUTICS ApS has published its annual report for 2022. The net result was DKK -473,890.
About DEFENSIN THERAPEUTICS ApS
DEFENSIN THERAPEUTICS ApS is a Danish company of the type Anpartsselskab based in København K, founded in 2013. The company is registered under the industry Forskning og eksperimentel udvikling inden for naturvidenskab og teknik. The management consists of Peter Hviid Nordkild. The board consists of Ejner Bech Jensen (chair), Matthew Alister Cooper, Peter Hviid Nordkild and Robert Ehehalt. The company's owners include NOVOZYMES A/S, PN INVESTMENT ApS and NEVE INVEST ApS. The company has 0 employees (2018). In 2025, the company reported a gross profit of DKK -538,913 and a net result of DKK -539,063 compared with DKK -130,534 the year before. Equity in the 2025 report amounted to DKK 774,437.